Welcome to our dedicated page for Seaport Therapeutics SEC filings (Ticker: SPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Seaport Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Seaport Therapeutics's regulatory disclosures and financial reporting.
Seaport Therapeutics director Sandra E. Peterson reported her initial holdings of stock options in Seaport Therapeutics, Inc. The filing lists two option grants to buy Common Stock: one covering 12,258 underlying shares at an exercise price of $10.31, and another covering 77,042 underlying shares at $7.39.
For the 12,258-share option, one-third of the underlying shares vested on December 2, 2025, with the rest vesting in 24 equal monthly installments, subject to her continued service. The 77,042-share option is scheduled to vest and become exercisable on February 24, 2027, also subject to continued service, with expiration dates in 2036 and 2034 respectively.
Seaport Therapeutics, Inc. director Sharon Mates has filed an initial Form 3 insider ownership report. The provided data show no reported transactions and no derivative positions, indicating this filing is primarily an administrative disclosure of insider status rather than a record of trading activity.
Seaport Therapeutics director Denice Torres has reported her existing equity awards and preferred shares in a Form 3. She holds stock options tied to 12,258 shares of Common Stock with a $10.31 exercise price expiring on February 23, 2036, and additional options tied to 77,042 shares at a $3.05 exercise price expiring on June 3, 2034. Vesting for these options occurs over time, with one grant beginning to vest on April 28, 2025 and another vesting on February 24, 2027, subject to continued service. A revocable trust associated with her holds Series B Preferred Stock convertible into 13,406 shares of Common Stock without additional payment, and she disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest.
Seaport Therapeutics, Inc. executive Lauren White, the Chief Financial Officer, has filed an initial ownership report that lists her existing equity interests in the company rather than new trades. The filing shows multiple stock option awards and a preferred stock position that can convert into common shares.
White holds stock options directly over 63,680 shares of common stock at an exercise price of $10.31 per share and additional options over 8,331 and 429,840 shares at an exercise price of $7.39 per share, each with long-dated expirations in 2034 and 2036. Vesting schedules extend over several years, with some options already fully vested and others vesting in monthly installments tied to her continued service.
Indirectly, through the Lauren Anne White Living Trust, she has 6,702 shares of Series B Preferred Stock, each convertible into common stock on a one-for-3.1407 basis and automatically convertible into the number of common shares shown upon the closing of the company’s initial public offering, without additional payment. She disclaims beneficial ownership of these preferred shares beyond any pecuniary interest.
Seaport Therapeutics, Inc. reports ARCH-affiliated initial holdings in preferred stock that is convertible into common shares. ARCH Venture Fund XII, L.P. holds Series B Preferred Stock representing 2,681,265 underlying shares of Common Stock and Series A-2 Preferred Stock representing 2,513,686 underlying shares, all as indirect ownership.
Each share of Series A-2 Preferred Stock and Series B Preferred Stock is convertible into Common Stock on a one-for-3.1407 basis at the option of the holder and will automatically convert into the stated numbers of common shares upon the closing of the company’s initial public offering, with no additional consideration and no expiration date. The structure runs through ARCH Venture Partners XII, L.P. and ARCH Venture Partners XII, LLC, and investment committee members Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen disclaim beneficial ownership beyond any pecuniary interest.
Seaport Therapeutics, Inc. General Counsel Lana Gladstein filed an initial ownership report showing derivative stakes in Seaport’s equity. She holds stock options linked to 63,680, 26,533 and 246,760 shares of common stock at exercise prices of $10.31, $7.39 and $3.05 per share, expiring between 2034 and 2036. She also holds Series B Preferred Stock convertible into 33,515 common shares on a one-for-3.1407 basis, which automatically converts into common stock upon the company’s initial public offering without additional payment. Footnotes explain that one option grant is fully vested, while the others vest over four years in monthly installments, contingent on her continued service.
Seaport Therapeutics, Inc. executive Michael Cunyuan Chen, Chief Scientific Officer, reported his existing equity holdings in a Form 3. He holds several stock options over Common Stock, including options covering 63,680 shares at an exercise price of $10.3100 per share expiring in 2036 and 400,618 shares at $3.0500 per share expiring in 2034. Additional options cover 86,267 and 18,042 underlying shares at an exercise price of $7.3900 with expirations in 2035 and 2034. He also holds Series B Preferred Stock that is convertible into 3,351 shares of Common Stock on a one-for-3.1407 basis, with automatic conversion upon the closing of the company’s initial public offering as described. Footnotes indicate these options vest over time, with some tranches already fully vested and exercisable.
Seaport Therapeutics director Robert J. Hombach reported his holdings of stock options tied to the company’s common stock. He holds options covering 12,258 underlying shares at an exercise price of $10.31 per share that expire on February 23, 2036, and options covering 77,042 underlying shares at $7.39 per share that expire on March 2, 2035.
According to the vesting terms, one grant vests one-third of its underlying shares on March 25, 2026, with the balance vesting in 24 equal monthly installments, while another grant vests in full on February 24, 2027, in each case conditioned on his continued service.
Seaport Therapeutics, Inc. Chief Medical Officer Antony Loebel filed an initial Form 3 showing his derivative and preferred equity interests in the company. He holds stock options over 63,680 shares of common stock at an exercise price of $10.3100 per share, 5,306 shares at $7.3900, and 539,293 shares at $3.0500, all held directly. The filing also reports 20,109 shares of Series B Preferred Stock, which are convertible into common stock on a one-for-3.1407 basis and will automatically convert into the number of shares shown upon the closing of the company’s initial public offering without further payment. Footnotes explain that one option grant vests 25% on July 18, 2025 with the remainder in 36 equal monthly installments, another is fully vested and exercisable, and a third vests in 48 equal monthly installments following February 24, 2026, all subject to his continued service.